Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis

PURPOSE: The development of acquired resistance to the first-line epidermal growth factor-tyrosine kinase inhibitor (EGFR-TKI) treatment in non-small-cell lung cancer (NSCLC) is inevitable, and most of these patients needed second-line chemotherapy. Furthermore, the optimum chemotherapeutic regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhihua, Guo, Haiyan, Lu, Yiyu, Hu, Jianxin, Luo, Haitao, Gu, Weiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027845/
https://www.ncbi.nlm.nih.gov/pubmed/29983578
http://dx.doi.org/10.2147/OTT.S160147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027845/
https://www.ncbi.nlm.nih.gov/pubmed/29983578
http://dx.doi.org/10.2147/OTT.S160147

Ejemplares similares